Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 369,000 shares, a decline of 10.3% from the November 15th total of 411,600 shares. Based on an average trading volume of 89,100 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC boosted its stake in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the period. Westside Investment Management Inc. increased its holdings in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management lifted its position in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the last quarter. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $31,000. Finally, Virtu Financial LLC bought a new stake in shares of Anixa Biosciences during the 3rd quarter worth $34,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Price Performance

NASDAQ ANIX traded down $0.08 during mid-day trading on Friday, hitting $2.85. The company’s stock had a trading volume of 51,348 shares, compared to its average volume of 109,167. The firm has a market capitalization of $91.71 million, a P/E ratio of -7.31 and a beta of 0.82. Anixa Biosciences has a 52-week low of $2.14 and a 52-week high of $5.13. The stock’s fifty day simple moving average is $3.22 and its two-hundred day simple moving average is $3.03.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANIX. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.